Your fact-checks will appear here
The text mentions that pharmacokinetic modeling and trials for malaria transmission have explored regimens to extend time above mosquitocidal thresholds.
Ivermectin is FDA‑approved for a small set of parasitic indications in humans—oral tablets for certain internal worms and topical formulations for external parasites and some skin conditions—but it is...
Ivermectin is FDA‑approved in humans for specific antiparasitic indications: oral tablets (Stromectol) for intestinal strongyloidiasis and onchocerciasis, and topical formulations for certain skin con...
Ivermectin can cause common, usually mild adverse effects such as headache, nausea, dizziness, diarrhea, and skin rash when given at approved human doses . Serious but rare harms include neurological ...
Ivermectin formulations and doses differ by species and by indication; human-approved products are single-dose oral tablets or topical creams with standard weight‑based dosing (generally 150–200 µg/kg...
Randomized trials that directly tested ivermectin as post‑exposure prophylaxis (PEP) for SARS‑CoV‑2 are few, heterogeneous in design, and report mixed results — one reported a large protective effect ...
A large and disparate body of clinical research tested ivermectin for COVID‑19 using regimens ranging from single low antiparasitic doses (≈150–200 μg/kg) to multi‑day high‑dose courses (including stu...
Raising ivermectin concentrations in humans can be approached by higher or more frequent oral dosing, formulation and route changes (controlled‑release, parenteral or inhaled delivery), and pharmacoki...
Clinical trials and protocols demonstrate that ivermectin has been given to humans at doses above 400 μg/kg—ranging from multiple trials testing 600 μg/kg and planned 1,200 μg/kg regimens to a formal ...
Randomized trials and dozens of meta-analyses have examined ivermectin for COVID‑19, producing contradictory signals: early meta‑analyses reported large mortality and recovery benefits while later, la...
Regulators including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the World Health Organization (WHO) do not recommend ivermectin for prevention or treatment of...
Randomized trials of ivermectin for COVID-19 and other indications report adverse events spanning neurological, gastrointestinal, dermatologic, ocular, and systemic (including multiorgan failure) cate...
Cumulative exposure to ivermectin raises toxicity risk primarily by increasing systemic drug levels, exposing vulnerable life stages, and enabling subclinical damage that may emerge over time — patter...
Clinical studies that describe "chronic" ivermectin use do not have a single standardized threshold; in the human trials reviewed, most chronic-use patterns meant multi-day or repeated dosing (for exa...
Completed randomized trials that tested ivermectin explicitly as prophylaxis against SARS‑CoV‑2 infection are few, small, and heterogeneous in design; the clearest randomized pre‑exposure prophylaxis ...
Randomized and non-randomized clinical trials have tested ivermectin across a range of doses and disease severities for COVID-19; most peer‑reviewed randomized controlled trials (RCTs) and several met...
Regulatory bodies approve ivermectin for human parasitic infections at standard oral doses around 150–200 µg/kg (0.15–0.2 mg/kg) for one or two doses, and do not authorize it for prevention or treatme...
Randomized trials of ivermectin for COVID‑19 have been numerous but heterogeneous in dose, duration and quality; large, well‑powered outpatient trials found no clinical benefit, higher‑dose trials sho...
Social media amplification of hopeful, emotive claims and politically coded messaging materially increased public demand for ivermectin — including veterinary formulations — during the COVID-19 pandem...
Poison control centers and emergency departments documented a clear uptick in human exposures to ivermectin during the COVID-19 era, with multiple case series and surveillance projects showing that ma...
Randomized and observational studies have tested five‑day ivermectin regimens almost exclusively in the context of COVID‑19, producing a patchwork of contradictory results: small trials from Banglades...